We found that CDAHFD-fed remarkably enhanced M1-polarized macrophages, as indicated by IHC staining of IL-12A and IRF5 (Figures 4A,B) and by analysis of the IL-12+ area and IRF-5+ areas in liver sections (Figures 4C,D); however, myricetin-treated NASH mice inhibited M1 macrophage phenotype as determined by M1-polarized markers. This evidence concerns the gene IRF5 and metabolic dysfunction-associated steatohepatitis.